Eli Lilly Reports P-III Study (TRAILBLAZER-ALZ 2) Results of Donanemab for the Treatment of Early Alzheimer's Disease
- The P-III study evaluating donanemab vs PBO in 1736 patients aged 60-85yrs. The trial met its 1EPs & 2EPs that measures slowed cognitive & functional decline
- The prespecified secondary analyses showed 47% vs 29% no decline on CDR-SB, patients completed their course of treatment (52% by 1yr. vs 72% by 18mos.) & achieved plaque clearance, 40% less decline in the ability to perform activities of daily living @18mos., 39% lower risk of progressing to the next stage of disease
- The study enrolled fewer individuals (n=552) with high baseline tau levels reflecting a later stage of the disease progression. In a separate primary analysis, high tau patients were combined with the intermediate tau population while positive results were seen across all clinical EPs in the combined population
Ref: Eli Lilly | Image: Eli Lilly
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.